[Preeclampsia and benefit form magnesium sulfate. About 105 cases]. / Sulfate de magnésium en prévention de l'éclampsie. À propos de 105 cas.

OBJECTIVES: The aim of this study was to determine the amount of magnesium sulfate involved when we diagnose a severe preeclampsia in pregnant women. Other goals were to know what the MgSO4 side-effects and complications are, and what benefits this treatment brings to prevent an eclampsia. PATIENTS AND METHODS: This retrospective and descriptive study was conducted for 7 years. We identified 105 women treated by MgSO4 out of 560 preeclampsia cases. To prevent eclampsia, those women were administrated MgSO4 before, during or after labor. All data about hospitalization term and MgSO4 term administration were collected in order to understand if MgSO4 side-effects for the women and the fetus occurred before, during or after labor. Those tables are compared with the MgSO4 administered dosages. RESULTS: MgSO4 isn't systematically used in all the preeclampsia cases. Forty percent of women under treatment presented low side effects. Overdoses, encountered in 31.4% of cases, regressed as soon as the MgSO4's perfusion was stopped. No major complications were noted. Only 0.95% of women treated by MgSO4 presented an eclampsia. DISCUSSION AND CONCLUSION: MgSO4 administered only to women having a neurological preeclampsia, within therapeutic doses and with rigorous monitoring, does not bring deleterious effects to the mother or newborn baby. Consequently, MgSO4's benefits were above the risks.

Quality of life in Iranian patients with acne.

Acne is a chronic inflammatory disease of pilosebaceous units. Although the acne isnot a life threatening disease, studies have revealed that it has significant effect on self-image and quality of life. The purpose of this paper was to investigate the health-related quality of life in patients with acne in an Iranian context. Dermatology Life Quality Index (DLQI) and Cardiff Acne Disability Index (CADI) were used for measuring quality of life, and severity of acne was measured by Global Acne Grading System (GAGS). The mean (±SD) of DLQI and CADI scores was 6.42 (±4.77) and 5.97 (±2.97), respectively. Acne influenced the quality of life in 51.8% of patients from moderate to very much, and the quality of life was affected by the severity of acne (P < 0.01). Since acne has significant effects on patient's quality of life, the management of patients with acne requires more attention to different aspects of quality of life.